Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
The Board of Cann Global Limited (ASX:CGB) wishes to update our shareholders on the operations of its 55% owned subsidiary Cann Global Asia Pty Ltd, and its activities in Laos PDR.
Fiji Kava Ltd (ASX:FIJ), Australian-Fijian medicinal kava health and wellness company which produces natural 'noble kava' products, today announced the signing of a Memorandum of Understanding (MOU) with PMM Company Limited to explore future opportunities to supply Fiji Kava's noble kava extract and products to the Chinese complementary medicine, personal care and pharmaceutical industries.
On 30 April 2020, Cann Global Ltd (ASX:CGB) lodged the Company's quarterly activities and cashflow reports for the period ended 31 March 2020. This amendment includes an updated cashflow report.
In October 2019, Austrade published a report on Australia's food innovators which Cann Global Limited (ASX:CGB), through its subsidiaries T12 and HHC, is very excited to be a part of.
The South African group, Labat Africa Ltd (JSE:LAB) which announced last year it was entering the medical CANNABIS market, is gaining the interest of High net worth and institutional investors in London and New York.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement.
